Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Drug Industry Expects No Additional Budget Benefits

This article was originally published in PharmAsia News

Executive Summary

India's pharmaceutical industry does not expect any particular benefit from the Union Budget 2008 being developed by a government facing upcoming national elections. The government has announced several populist health-care measures to benefit the public at large, including some favored by the Pharmaceutical and Biotechnology Industry. But the benefits are not expected to be as high as suggested. Benefits include weighted research-and-development deductions, reduced custom duty on certain drugs and reduction of excise duties on all drugs. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts